KRYS Stock Analysis: Krystal Biotech | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 10.929m USD | 12M Return: 141.9% | US5011471027 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 70.4M
Qual. Beats: 0
Rev. Trend: 83.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 8.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a U.S.-based, commercial-stage biotechnology company that discovers, develops, manufactures, and commercializes genetic medicines targeting diseases with high unmet medical needs. The company is vertically integrated across the full value chain, from R&D through manufacturing and commercialization, a relatively unusual structure for a small-cap biotech. It is headquartered in Pittsburgh, Pennsylvania, and was founded in 2016.
The companys lead and only commercial product is VYJUVEK (beremagene geperpavec-svdt, or B-VEC), approved in the U.S. for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. VYJUVEK is notable as one of the first topical gene therapies to receive regulatory approval, positioning Krystal within the rare/orphan disease and gene therapy segments of the biotechnology sector. Treatment of DEB addresses a small patient population with historically no approved disease-modifying therapies.
Beyond VYJUVEK, Krystal maintains a diversified clinical pipeline of genetic medicine candidates spanning dermatology, ophthalmology, pulmonology, and oncology. Programs include KB803 for ocular complications of DEB, KB801 for neurotrophic keratitis, KB407 (Phase 1) for cystic fibrosis, KB111 for Hailey-Hailey disease, KB304 for dynamic wrinkles, KB301 (Phase 2) for aesthetic skin conditions, KB707 (Phase 1/2) for solid tumors and anti-PD-1 relapsed/refractory settings, and KB408 (Phase 1) for Alpha-1 antitrypsin deficiency. The breadth of indications reflects a platform-based approach to gene therapy, applying a common delivery technology across multiple rare and specialty disease targets.
- VYJUVEK sales growth drives commercial momentum in DEB market
- KB407 cystic fibrosis and KB707 oncology pipeline data readouts ahead
- ASTRA facility expansion boosts in-house gene therapy manufacturing capacity
| Net Income: 241.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 0.89 > 1.0 |
| NWC/Revenue: 211.6% < 20% (prev 210.0%; Δ 1.61% < -1%) |
| CFO/TA 0.18 > 3% & CFO 272.3m > Net Income 241.5m |
| Net Debt (-836.8m) to EBITDA (204.6m): -4.09 < 3 |
| Current Ratio: 8.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.7m) vs 12m ago 3.05% < -2% |
| Gross Margin: 93.34% > 18% (prev 93.37%; Δ -0.03% > 0.5%) |
| Asset Turnover: 33.38% > 50% (prev 31.55%; Δ 1.83% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.62 (Total Current Assets 1.06b - Total Current Liabilities 127.4m) / Total Assets 1.50b |
| B: 0.09 (Retained Earnings 134.9m / Total Assets 1.50b) |
| C: 0.15 (EBIT TTM 197.9m / Avg Total Assets 1.32b) |
| D: 9.60 (Book Value of Equity 1.36b / Total Liabilities 141.5m) |
| Altman-Z'' = 15.46 = AAA |
| DSRI: 1.01 (Receivables 138.7m/111.4m, Revenue 440.5m/359.2m) |
| GMI: 1.00 (GM 93.37% / 93.34%) |
| AQI: 1.53 (AQ_t 0.19 / AQ_t-1 0.12) |
| SGI: 1.23 (Revenue 440.5m / 359.2m) |
| TATA: -0.02 (NI 241.5m - CFO 272.3m) / TA 1.50b) |
| Beneish M = -2.54 (Cap -4..+1) = A |
As of September 09, 2026, the stock is trading at USD 351.26 with a total of 255,600 shares traded. Over the past week, the price has changed by -2.25%, over one month by +5.93%, over three months by +16.40% and over the past year by +141.91%.
Current recommended Stop Loss: 334.20 (which is 4.9% or 1.4 ATR below the current price).
Krystal Biotech has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy KRYS.
- StrongBuy: 8
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 385 | 9.6% |
P/E Trailing = 45.6403
P/E Forward = 50.0
P/S = 24.8108
P/B = 7.9237
Revenue TTM = 440.5m USD
EBIT TTM = 197.9m USD
EBITDA TTM = 204.6m USD
Long Term Debt = 7.04m USD (estimated: total debt 8.85m - short term 1.81m)
Short Term Debt = 1.81m USD (from shortTermDebt, last quarter)
Debt = 8.85m USD (from shortLongTermDebtTotal, last quarter) (leases 8.85m already included)
Net Debt = -836.8m USD (calculated: Debt 8.85m - CCE 845.6m)
Enterprise Value = 10.1b USD (10.9b + Debt 8.85m - CCE 845.6m)
Interest Coverage Ratio = unknown (Ebit TTM 197.9m / Interest Expense TTM 0.0)
EV/FCF = 39.15x (Enterprise Value 10.1b / FCF TTM 257.8m)
FCF Yield = 2.55% (FCF TTM 257.8m / Enterprise Value 10.1b)
FCF Margin = 58.52% (FCF TTM 257.8m / Revenue TTM 440.5m)
Net Margin = 54.82% (Net Income TTM 241.5m / Revenue TTM 440.5m)
Gross Margin = 93.34% ((Revenue TTM 440.5m - Cost of Revenue TTM 29.3m) / Revenue TTM)
Gross Margin QoQ = 94.60% (prev 94.57%)
Tobins Q-Ratio = 6.73 (Enterprise Value 10.1b / Total Assets 1.50b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.85m)
Taxrate = 17.12% (11.3m / 66.1m)
NOPAT = 164.0m (EBIT 197.9m * (1 - 17.12%))
Current Ratio = 8.32 (Total Current Assets 1.06b / Total Current Liabilities 127.4m)
Debt / Equity = 0.01 (Debt 8.85m / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = -4.09 (Net Debt -836.8m / EBITDA 204.6m)
Debt / FCF = -3.25 (Net Debt -836.8m / FCF TTM 257.8m)
Total Stockholder Equity = 1.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.30% (Net Income 241.5m / Total Assets 1.50b)
RoE = 19.34% (Net Income TTM 241.5m / Total Stockholder Equity 1.25b)
RoCE = 15.77% (EBIT 197.9m / Capital Employed (Equity 1.25b + L.T.Debt 7.04m))
RoIC = 12.12% (NOPAT 164.0m / Invested Capital 1.35b)
WACC = 8.11% (E(10.9b)/V(10.9b) * Re(8.12%) + D(8.85m)/V(10.9b) * Rd(0.0%) * (1-Tc(0.17)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.26 | Cagr: 2.05%
[DCF] Terminal Value 77.97% ; FCFF base≈228.8m ; Y1≈262.3m ; Y5≈386.1m
[DCF] Fair Price = 224.6 (EV 5.81b - Net Debt -836.8m = Equity 6.65b / Shares 29.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: 83.42 | Revenue CAGR: 195.6% | SUE: -0.42 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.00 | Chg30d=-10.20% | Revisions=-12% | Analysts=10
EPS current Year (2026-12-31): EPS=7.87 | Chg30d=-6.88% | Revisions=-18% | GrowthEPS=+15.0% | GrowthRev=+31.7%
EPS next Year (2027-12-31): EPS=9.40 | Chg30d=-6.13% | Revisions=-18% | GrowthEPS=+19.5% | GrowthRev=+27.7%
[Analyst] Revisions Ratio: -21% (up=8, down=13)